Biogen, Genentech's Rituxan Fails New Study
This is the second clinical setback for Rituxan in the last two weeks. On April 15, the companies announced that a late-stage study in primary progressive multiple sclerosis also failed.
In this most recent study, patients with systemic lupus erythematosus (SLE), commonly called lupus, failed to respond any better to Rituxan vs. placebo after one year of treatment, the companies said. None of the study's six secondary endpoints were successful, either.
A separate phase III study of Rituxan in patients with lupus nephritis, a different form of the disease, is ongoing.Lupus has proven to be a stubborn disease to overcome, leaving in its wake a long list of clinical trial failures. With that said, most analysts did not include Rituxan-lupus revenue in their financial models for either Genentech or Biogen Idec. However, lupus and multiple sclerosis were seen as long-term growth opportunities for Rituxan, so the recent study failures take a bite out of that prospect. Genentech and Biogen Idec reported 2007 Rituxan sales of $2.29 billion in the U.S., primarily as a treatment for the blood cancer non-Hodgkin's lymphoma. The drug is also approved to treat rheumatoid arthritis. Genentech shares were down 5.8% at $68.93 in early trading Tuesday. Biogen Idec was trading down 5% at $61.43. Know What You Own: Genentech has a deep cancer drug pipeline, with about 15 experimental drugs in phase I, II or III trials. Among the biotech company's cancer drug partners are Curis (CRIS), Immunogen (IMGN), Abbott Labs (ABT), Seattle Genetics (SGEN) and Exelixis (EXEL).
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV